
Humacyte (HUMA) Stock Forecast & Price Target
Humacyte (HUMA) Analyst Ratings
Bulls say
Humacyte is positioned for long-term success due to its regained ex-U.S. rights for Symvess, giving the company more flexibility to tailor partnerships and potential for non-dilutive capital. The company's advancing global expansion, with the MAA acceptance for Symvess in Israel and ongoing efforts in other international markets, also supports its potential growth. However, risk factors such as clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks should still be monitored as the company progresses.
Bears say
Humacyte is currently developing and commercializing acellular tissue engineered vessels for various indications, including vascular trauma and hemodialysis access. While the company has made progress in terms of regulatory approvals and international partnerships, their product sales have been relatively low and they have yet to achieve profitability. Additionally, their planned expansion into other indications and geographic markets may face challenges and competition from other vascular repair technologies.
This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.
Humacyte (HUMA) Analyst Forecast & Price Prediction
Start investing in Humacyte (HUMA)
Order type
Buy in
Order amount
Est. shares
0 shares